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Purpose of the study
Optimal time of HAART initiation is still unknown.
Several studies investigating this issue showed inconsis-
tent results. Our study investigated whether there is a
clinical benefit as to treated patients (pts) by an earlier
start of therapy at CD4 between 350-449c/µl, compared
to the range of 250-349c/µl. An analysis was conducted
on basis of the open, retrospective and prospective,
multi-center and nationwide cohort of the Competence
Network for HIV/AIDS.
Methods
For analysis, pts had to be observed at least 3 months
before initiation of HAART. Medication had to start later
than 1996, with at least three substances. At time of ther-
apy start (to), pts had to have 250c/µl <CD4-cells<450c/
µl, no prior AIDS defining conditions and CD4 cells
never below 200c/µl. Afterwards, pts were stratified in
groups by initial CD4 cells between 250-349c/µl (group
1) and 350-449c/µl (group 2). Primary outcomes death,
AIDS and first drop of CD4 cell count/µl<200 cells were
evaluated as censored event times between to and the
date of first event resp. last observation. Time dependent
probabilities of event free intervals since start of HAART
were estimated by Kaplan-Meier estimation, compared
by Log-rank-tests. Cox-regression models were fitted,
adjusted for time since infection.
Summary of results
822 pts met inclusion criteria. Group 1 consisted of 526
pts, group 2 of 296. Mean observation time in group 1 was
5.1 years/pt (2,683 years overall), in group 2 4.9 years/pt
(1,450 y overall). In group 1, 0.64 deaths occurred per
100 pt years vs. 0.17 events in group 2. 1.38 AIDS events
were developed per 100 pt years vs. 0.78 events in group 2.
In group 1, 2.64 per 100 pts years dropped <200c/µl vs.
0.77 in group 2. Kaplan-Meier estimations showed border-
line significant difference as to developing death (ten years
probabilities for having no event as to death: group1 94%,
group2: 97%, p=0.063), significant difference as to CD4
drop<200c/µl (group1 80%, group2: 94%, p=0.0004), but
no significant differences as to AIDS (group1 92%, group2:
90%, p=0.219). Hazard ratio (group 2 vs. 1) was significant
for CD4 drop<200c/µl (0.302, p=0.001), but not for death
(0.268, p=0.0829) and AIDS (0.577, p=0.153).
Conclusions
Results showed a tendency for better outcome of pts by
start of therapy with CD4 cell count ≥350c/µl regarding
death, clear evidence regarding first CD4 drop <200.
These results may be a hint to start therapy earlier.
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